Monitor the company's 2026 10-Q filings for any changes in executive compensation philosophy or governance practices that may result from the new board composition and CEO transition. The strong 2025 performance and successful leadership transition suggest operational stability, but the lack of financial restatements or material changes in this amendment indicates no immediate regulatory or accounting concerns.
Price Chart
Executive Summary
This is an amended 10-K filing for Jazz Pharmaceuticals that primarily updates Part III to include proxy statement information for the 2026 Annual General Meeting. The amendment does not contain restatements, financial corrections, or material changes to the original filing. It provides detailed information on executive compensation, board composition, and corporate governance, reflecting the CEO transition from Bruce Cozadd to Renee Gala in 2025.
Key Facts
- Amendment No. 1 to the 10-K for fiscal year 2025, filed to include Part III information previously incorporated by reference from the proxy statement.
- No restatements, financial corrections, or material changes to the original 10-K filing were made.
- The filing details the 2025 executive compensation program, including a 150% achievement of corporate objectives leading to maximum bonus payouts.
- The CEO transition was completed in 2025, with Bruce Cozadd retiring as CEO on September 14, 2025, and Renee Gala assuming the role on August 11, 2025.
- The company reported strong 2025 performance with record financials, including Xywav net sales of $1.66 billion and Epidiolex/Epidyolex sales of $1.06 billion.
Financial Impact
The amendment itself has no financial impact. The underlying 2025 financials show strong performance with Xywav sales at $1.66B and Epidiolex/Epidyolex at $1.06B.
Risk Factors
- Insider selling activity (one sell for $701K in the last 30 days) could indicate reduced confidence among executives.
- The company's reliance on a few key products (Xywav, Epidiolex) for revenue creates concentration risk.
- The recent CEO transition, while completed, could lead to strategic shifts that may not be immediately apparent.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001628280-26-027205 |
| Document: jazz10-kafy2025exhibit314.htm | 0001628280-26-027205 |
| Document: jazz10-kafy2025exhibit313.htm | 0001628280-26-027205 |
| Document: 0001628280-26-027205-index-headers.html | 0001628280-26-027205 |
| Document: 0001628280-26-027205-index.html | 0001628280-26-027205 |
| Document: 0001628280-26-027205.txt | 0001628280-26-027205 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Press Release | $213.76 $211.97 | ▼ −0.84% | ▼ −1.36% | $210.99 (−1.30%) |
Oct 9, 2026 17d ago | 8-K | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 8, 2026 17d ago | 144 | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 6, 2026 19d ago | 144 | $231.19 $222.45 | ▼ −3.78% | ▼ −3.36% | $210.99 (−8.74%) |
Oct 1, 2026 24d ago | 144 | $235.67 $236.04 | ▲ +0.16% | ▼ −0.52% | $210.99 (−10.47%) |
Sep 15, 2026 5w ago | 8-K | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 14, 2026 5w ago | Insider Cluster | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $245.80 $245.87 | ▲ +0.03% | ▲ +0.47% | $210.99 (−14.16%) |
Sep 2, 2026 7w ago | Insider Cluster | $247.57 $246.81 | ▲ +0.30% | ▼ −0.08% | $210.99 (+14.78%) |
Aug 31, 2026 7w ago | 144 | $243.71 $245.57 | ▲ +0.76% | ▲ +0.32% | $210.99 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers